WD-40 (NASDAQ:WDFC – Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 5.200-5.450 for the period, compared to the consensus EPS estimate of 5.360. The company issued revenue guidance of $600.0 million-$630.0 million, compared to the consensus revenue estimate of $623.0 million. WD-40 also updated its FY25 […]

NeoGenomics (NASDAQ:NEO – Get Free Report) updated its FY 2024 earnings guidance on Friday. The company provided earnings per share guidance of 0.080-0.100 for the period, compared to the consensus earnings per share estimate of 0.100. The company issued revenue guidance of $655.0 million-$667.0 million, compared to the consensus revenue estimate of $662.0 million. NeoGenomics […]

WD-40 (NASDAQ:WDFC – Get Free Report) updated its FY25 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $5.20-$5.45 for the period, compared to the consensus estimate of $5.36. Analyst Upgrades and Downgrades A number of brokerages have issued reports on WDFC. DA Davidson reiterated a “buy” rating and issued a […]

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.950-5.350 for the period, compared to the consensus estimate of 4.690. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Halozyme Therapeutics […]

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $4.95-$5.35 for the period, compared to the consensus estimate of $4.83. The company issued revenue guidance of $1.150-$1.225 billion, compared to the consensus revenue estimate of $1.16 billion. Halozyme Therapeutics also updated […]

Helen of Troy (NASDAQ:HELE – Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 7.150-7.400 for the period, compared to the consensus EPS estimate of 7.210. The company issued revenue guidance of $1.9 billion-$1.9 billion, compared to the consensus revenue estimate of $1.9 […]